阿托伐他汀联合依折麦布治疗冠心病合并高胆固醇血症临床分析

Clinical Analysis of Atorvastatin Statin combined with Ezetimibe for Coronary Heart Disease with Hypercholesterolemia

目的:探讨阿托伐他汀联合依折麦布治疗冠心病合并高胆固醇血症的临床疗效和安全性。方法:将笔者所在医院收治的冠心病患者72例随机分为观察组和对照组,各36例,对照组以阿托伐他汀口服治疗,观察组在对照组的基础上加用依折麦布,治疗2周为1个疗程,3个疗程后根据两组患者胆固醇、炎症、肝肾功能指标水平及临床不良反应发生率综合评价其疗效和安全性。结果:高胆固醇和炎症改善:治疗后,观察组患者血清TC、LDL-C及hs-CRP水平显著低于对照组(P<0.05),两组患者HDL-C水平差异无统计学意义(P>0.05);肝肾损伤和不良反应:治疗后,观察组患者ALT、UN水平显著低于对照组(P<0.05),不良反应发生率显著小于对照组(P<0.05),两组患者CRE水平差异无统计学意义(P>0.05)。结论:阿托伐他汀联合依折麦布治疗冠心病合并高胆固醇血症,疗效确切,临床毒副作用小,安全性高,适用于普及和推广。

Objective： To investigate the clinical efficacy and safety of atorvastatin statin combined with ezetimibe for the treatment of coronary heart disease with hypercholesterolemia. Method： 72 cases of patients with coronary heart disease were randomly divided into two groups. 36 cases in the control group were treated with atorvastatin statins, while the other 36 eases in the observation group were treated with ezetimibe on the basis of t atorvastatin statins. Every two weeks was a course of treatment, and the comprehensive evaluation of efficacy and safety were estimated and compared based on the incidence of adverse reactions, and the liver and kidney function indicators after three courses. Result： High cholesterol and inflammation： After treatment, the serum TC, LDL-C and hs-CRP levels of the observation group were significantly lower than the control group （ P〈0.05 ）, while there was no significant difference in the two groups of patients with HDL-C levels （ P〉0.05 ） ; liver and kidney damage and adverse reactions ： After treatment, the ALT UN level of the observation group were significantly lower than the control group （ P〈0.05 ）, while there was no significant difference in the two groups of patients with CRE levels （ P〉O.05 ） .The incidence of adverse reactions of the observation group was significantly less than the control group （ P〈O.05 ） . Conclusion： It is an efficient method with little clinical side effects for atorvastatin statin combined with ezetimibe to treat coronary heart disease with hypercholesterolemia which is worth to l^e promoted.